-31.35 (-1.84%) Sun Pharmaceutical Industries has informed that it enclosed a copy of the Press Release about Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial of MM-II in Patients with Painful Knee Osteoarthritis (OA), which shall be released after this intimation.
The above information is a part of company’s filings submitted to BSE.